Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326186 | 0.87 | MAPT (0.49) | SMN1; SMN2RAB9ANPC1KMT2ANFKB1 | |
| SCHEMBL14845613 | 0.87 | RAB9A (0.43) | SMN1; SMN2RAB9ANPC1KMT2ANFKB1 | |
| SCHEMBL13788542 | 0.86 | HTT (0.56) | NPC1KMT2AMAPTPOLBLMNA | |
| SCHEMBL13788580 | 0.85 | GCK (0.43) | SMN1; SMN2RAB9ANPC1KMT2ANFKB1 | |
| SCHEMBL4320354 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9ANPC1KMT2ANFKB1 | |
| SCHEMBL13788614 | 0.84 | ALDH1A1 (0.46) | SMN1; SMN2RAB9ANPC1KMT2ANFKB1 | |
| SCHEMBL4330329 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9ANPC1KMT2AMAPT | |
| SCHEMBL13933320 | 0.82 | MAPT (0.43) | SMN1; SMN2RAB9ANPC1KMT2ANFKB1 | |
| SCHEMBL13788611 | 0.81 | SLC2A1 (0.42) | SMN1; SMN2RAB9ANPC1KMT2ANFKB1 | |
| SCHEMBL4333034 | 0.80 | MAPK14 (0.40) | SMN1; SMN2RAB9ANPC1KMT2ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | COSTALES ABRAN (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | COSTALES ABRAN (US) | 2013-08-29 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-1682126-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1682126-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |
| EP-1682126-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005037273-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | BRAF, RAF1, ARAF | SMN1; SMN2 3544/4885RAB9A 1454/4885NPC1 4051/4885 |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | SMN1; SMN2 3544/4885RAB9A 1454/4885NPC1 4051/4885 |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | SMN1; SMN2 3544/4885RAB9A 1454/4885NPC1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.